-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy

Reuters·12/28/2025 23:30:33

Please log in to view news